Mepolizumab for Eosinophilic Fasciitis
NCT04305678 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2024-11-20
Summary
This is a proof of concept pilot study to investigate the efficacy of mepolizumab in the treatment of eosinophilic fasciitis.
Conditions
- Eosinophilic Fasciitis
Interventions
- DRUG
-
Mepolizumab
Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
Sponsors & Collaborators
- collaborator INDUSTRY
- lead OTHER
Principal Investigators
-
Jason C Sluzevich, M.D. · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-28
- Primary Completion
- 2023-02-15
- Completion
- 2023-02-15
- FDA Drug
- Yes
More Related Trials
-
An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients
NCT00274703 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
NCT03055195 ·Status: TERMINATED ·Phase: PHASE2
-
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
NCT00086658 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
NCT00097370 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children
NCT02377427 ·Status: COMPLETED ·Phase: PHASE2
-
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
NCT00244686 ·Status: NO_LONGER_AVAILABLE
-
Short Duration 6Fed Sponge For EoE Patients
NCT03354221 ·Status: WITHDRAWN ·Phase: NA
-
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
NCT03306043 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
NCT01705795 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT05152563 ·Status: WITHDRAWN ·Phase: PHASE3
-
Gastrointestinal STRING Test With Oral Immunotherapy
NCT04943744 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
NCT02007239 ·Status: WITHDRAWN ·Phase: PHASE2
-
eGPA and Local Inflammation Within the Ear, Nose and Throat Area
NCT06298448 ·Status: RECRUITING
-
Omalizumab to Treat Eosinophilic Gastroenteritis
NCT00084097 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
NCT00275613 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT03664960 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
NCT03496571 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
NCT00635089 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
NCT00123630 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels
NCT00851370 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04322604 ·Status: COMPLETED ·Phase: PHASE3
-
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368 ·Status: RECRUITING ·Phase: PHASE3
-
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
NCT00266565 ·Status: COMPLETED ·Phase: PHASE1/PHASE2